Form 4: Celularity Director Ling Receives RSU Grant

Celularity Inc. Director Geoffrey M.D. Ling was granted 19,231 restricted stock units, increasing his beneficial ownership to 256,026 shares.

Summary

• Director Geoffrey M.D. Ling of Celularity Inc. (CELU) reported an acquisition of 19,231 Class A Common Stock restricted stock units (RSUs).
• The transaction date for this grant was January 12, 2026.
• These RSUs were granted under the Celularity Inc. 2021 Equity Incentive Plan at a price of $0.00 per unit.
• Following this transaction, Ling's total beneficial ownership stands at 256,026 shares of Class A Common Stock.
• The RSUs are subject to vesting on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, contingent on continuous service.

Sentiment

Score: 7

Explanation: The grant of RSUs to a director is a positive event as it aligns management's interests with shareholders, but it is a routine compensation matter and not indicative of significant operational or financial news.

Positives

• The grant of restricted stock units aligns the director's long-term interests with those of the shareholders, promoting sustained performance.
• Equity compensation is a standard practice for retaining and incentivizing key personnel, including directors.

Future Outlook

The granted restricted stock units are expected to vest and become exercisable on the earlier of January 12, 2027, or the date of the next annual stockholder meeting, provided the reporting person maintains continuous service with the Issuer.

Industry Context

The grant of restricted stock units to a director is a common form of equity compensation across the biotechnology and pharmaceutical industries, designed to align leadership incentives with company performance and shareholder value.

Comparison to Industry Standards

• The structure of this RSU grant, with vesting tied to a one-year anniversary or the next annual meeting and continuous service, is a standard practice for director compensation in publicly traded companies, comparable to similar plans at companies like Gilead Sciences or Amgen.

Related Party Transactions

• Grant of 19,231 restricted stock units to Director Geoffrey M.D. Ling under the Celularity Inc. 2021 Equity Incentive Plan, representing a compensation transaction between the company and a related party.

Stakeholder Impact

• Shareholders may view this as a positive development, as it further aligns the director's financial interests with the company's long-term performance.
• Employees are not directly impacted by this specific director compensation event, but it reflects the company's overall compensation strategy.

Next Steps

• Vesting of the 19,231 restricted stock units on the earlier of January 12, 2027, or the next annual stockholder meeting, subject to continuous service.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice and does not provide new information to alter an investment thesis. It aligns the director's interests with shareholders but does not indicate a change in company fundamentals or outlook that would warrant a change in investment recommendation.

Keywords

Celularity Inc., CELU, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant